# Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

> **NCT06033118** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 25 (estimated)

## Conditions studied

- Combined Hepatocellular Cholangiocarcinoma

## Interventions

- **DRUG:** gemcitabine ,oxaliplatin,anlotinib,Sintilimab

## Key facts

- **NCT ID:** NCT06033118
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-08-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06033118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06033118, "Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06033118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*